Researchers synthesize chimeric peptide that elicits antitumor activity for cancer immunotherapy

Professor Yanfeng Gao’s crew from the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University possess designed and synthesized Pal-DMPOP, a chimeric peptide that can perhaps simultaneously block CD47/SIRPα and PD-1/PD-L1. This bispecific peptide elicits synergistic antitumor activity by bettering macrophages phagocytosis and activating CD8⁺ T cells. The findings are published in the journal Science China Life Sciences.

Although immune checkpoint inhibition has been shown to successfully suggested antitumor immunity in a technique of tumor forms, easiest a small subset of sufferers can clutch pleasure in PD-1/PD-L1 blockade. CD47 expressed on tumor cells protects them from phagocytosis by contrivance of interaction with SIRPα on macrophages, whereas PD-L1 dampens T cell-mediated tumor killing.

Also, it became once reported that macrophages can additionally suppose PD-1 to mediate a “make no longer exhaust me” stamp by contrivance of interaction with PD-L1 on tumor cells. When compared with antibodies, peptides possess better tumor penetration ability and straightforward to be synthesized. Ensuing from this truth, make of peptides dual-focusing on blockade of each PD-1/PD-L1 and CD47/SIRPα might perhaps toughen the efficacy of most cancers immunotherapy.

Read More

Tags: Researchers synthesize